The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Interim analysis.
 
Andrea Grace Bocobo
No Relationships to Disclose
 
Renee Wang
No Relationships to Disclose
 
Spencer Behr
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; GenVivo; More Health; Progenics
Research Funding - Cancer Targeted Technology
 
Julia C. Carnevale
No Relationships to Disclose
 
Pelin Cinar
No Relationships to Disclose
 
Eric Andrew Collisson
Stock and Other Ownership Interests - BloodQ; Clara Health; Guardant Health; Hint Health; Tatara Therapeutics
Consulting or Advisory Role - Merck
Research Funding - Ferro Oncology/Bridge Bio (Inst); Loxo/Bayer (Inst); Merck KGaA (Inst); Senti Biosciences (Inst)
 
Lawrence Fong
Consulting or Advisory Role - Atreca; BioAtla; Bolt Biotherapeutics; Nutcracker Therapeutics, Inc.; TeneoBio
Research Funding - Abbvie (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Wesley Allen Kidder
No Relationships to Disclose
 
Andrew H. Ko
Honoraria - Clinical Care Options; Dava Oncology; Elsevier; OncLive; PER; Pharmatecture; PlatformQ Health; Research to Practice; Xcenda
Consulting or Advisory Role - ERYTECH Pharma; Gilead Sciences; Gritstone Bio; Imugene; MORE Health; SynCoreBio
Speakers' Bureau - Clinical Care Options
Research Funding - AbGenomics International (Inst); Apexigen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Halozyme (Inst); Merck (Inst); Merrimack (Inst)
 
Kanti Pallav Kolli
Stock and Other Ownership Interests - Adient Medical
 
Megan Kennedy
No Relationships to Disclose
 
Angela Laffan
No Relationships to Disclose
 
Sheila Lindsay
No Relationships to Disclose
 
Sneha Nalla
No Relationships to Disclose
 
Gabriel Schwartz
Stock and Other Ownership Interests - Intercept Pharmaceuticals; Minerva Neurosciences; Sutter Medical Group
Honoraria - Eisai; Exelixis
Consulting or Advisory Role - Eisai; Exelixis
Speakers' Bureau - Exelixis
 
Julia Whitman
No Relationships to Disclose
 
Patricia Zendejas
No Relationships to Disclose
 
Li Zhang
Consulting or Advisory Role - Dendreon; Fortis; Unity Biotechnology
Travel, Accommodations, Expenses - Dendreon; Dendreon; Dendreon
 
Katherine Van Loon
Speakers' Bureau - Amgen; Physicans' Education Resource
Research Funding - Celgene (Inst); Celgene (Inst)
 
Chloe Evelyn Atreya
Stock and Other Ownership Interests - Pionyr
Consulting or Advisory Role - Array BioPharma; Pionyr
Research Funding - Bristol-Myers Squibb; Genentech (Inst); Guardant Health; Merck; Novartis
Travel, Accommodations, Expenses - Roche